Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 501–600 of 4,275
Chambers, C. R., Ritchie, S., Pereira, B. A., & Timpson, P. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13042 · Cited by 165
Chorioamniotic membrane senescence: a signal for parturition?
Behnia, F., Taylor, B. D., Woodson, M., Kacerovsky, M., Hawkins, H., Fortunato, S. J., Saade, G. R., & Menon, R. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.05.041 · Cited by 163
Biophysical properties of AKAP95 protein condensates regulate splicing and tumorigenesis
Li, W., Hu, J., Shi, B., Palomba, F., Digman, M. A., Gratton, E., & Jiang, H. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0550-8 · Cited by 163
Reorganization of chromosome architecture in replicative cellular senescence
Criscione, S. W., De Cecco, M., Siranosian, B., Zhang, Y., Kreiling, J. A., Sedivy, J. M., & Neretti, N. (2016) · Science Advances · doi:10.1126/sciadv.1500882 · Cited by 164
Curcumin, inflammation, ageing and age-related diseases
Sikora, E., Scapagnini, G., & Barbagallo, M. (2010) · Immunity & Ageing · doi:10.1186/1742-4933-7-1 · Cited by 164
“Cellular participants in low-grade inflammatory status not only include cells of the immune sytem but also other ones which have undergone genotoxic stress-induced senescence and secrete many inflammatory cytokines, to the so-called senescence-associated secretory phenotype (SASP) [9].”
BackgroundKandhaya-Pillai, R., Miro-Mur, F., Alijotas-Reig, J., Tchkonia, T., Kirkland, J. L., & Schwartz, S. (2017) · Aging · doi:10.18632/aging.101328 · Cited by 165
“Senescent cells can secrete a wide range of growth factors, cytokines, chemokines, extracellular matrix proteases, and degradative enzymes known as the senescence-associated secretory phenotype (SASP) or senescence messaging secretome [15-18].”
BackgroundYasuda, T., Koiwa, M., Yonemura, A., Miyake, K., Kariya, R., Kubota, S., Yokomizo-Nakano, T., Yasuda-Yoshihara, N., Uchihara, T., Itoyama, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108779 · Cited by 165
Epithelial-mesenchymal transition and inflammation at the site of the primary tumor
Dominguez, C., David, J. M., & Palena, C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.002 · Cited by 162
The dynamic biliary epithelia: Molecules, pathways, and disease
O’Hara, S. P., Tabibian, J. H., Splinter, P. L., & LaRusso, N. F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.011 · Cited by 162
Rai, T. S., Cole, J. J., Nelson, D. M., Dikovskaya, D., Faller, W. J., Vizioli, M. G., Hewitt, R. N., Anannya, O., McBryan, T., Manoharan, I., et al. (2014) · Genes & Development · doi:10.1101/gad.247528.114 · Cited by 162
“3 in senescent cells, and these are enriched in genes related to TNF signaling, a component of the SASP (Supplemental Fig.”
BackgroundInfluentialMuñoz, D. P., Yannone, S. M., Daemen, A., Sun, Y., Vakar-Lopez, F., Kawahara, M., Freund, A. M., Rodier, F., Wu, J. D., Desprez, P.-Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124716 · Cited by 162
“Consistent with ATM-dependent upregulation of SASP factors (52) and NKG2D-Ls (Figure 2E), ATM-deficient XRA SnCs failed to repress NKG2D expression (Figure 8B).”
InfluentialSelf-citationAlimbetov, D., Davis, T., Brook, A. J. C., Cox, L. S., Faragher, R. G. A., Nurgozhin, T., Zhumadilov, Z., & Kipling, D. (2016) · Biogerontology · doi:10.1007/s10522-015-9610-z · Cited by 162
“The SASP does not develop immediately after a senescence-inducing stimulus, but once established it can persist for long periods (Coppe et al. 2008; Rodier et al. 2009).”
BackgroundMethodInfluentialOncogene-induced senescence results in marked metabolic and bioenergetic alterations
Quijano, C., Cao, L., Fergusson, M. M., Romero, H., Liu, J., Gutkind, S., Rovira, I. I., Mohney, R. P., Karoly, E. D., & Finkel, T. (2012) · Cell Cycle · doi:10.4161/cc.19800 · Cited by 155
Signaling networks determining life span
Riera, C. E., Merkwirth, C., De Magalhaes Filho, C. D., & Dillin, A. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014451 · Cited by 161
“Despite the relatively small number of senescent cells in aged tissues, a unique senescence-associated secretory profile (SASP) including many proinflammatory cytokines might broadly impact organismal aging through endocrine or other cell nonautonomous regulation (177).”
BackgroundMitochondria: Are they causal players in cellular senescence?
Correia-Melo, C., & Passos, J. F. (2015) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2015.05.017 · Cited by 160
Cellular Senescence: From Mechanisms to Current Biomarkers and Senotherapies
Lucas, V., Cavadas, C., & Aveleira, C. A. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000622 · Cited by 160
Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells
Cahu, J., Bustany, S., & Sola, B. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.183 · Cited by 160
“senescence is referred as senescence-associated with secretory phenotype (SASP).(18) Similarly, western blot analyses showed a lasting phosphorylation of CHK2 after”
BackgroundNotch Signaling Mediates Secondary Senescence
Teo, Y. V., Rattanavirotkul, N., Olova, N., Salzano, A., Quintanilla, A., Tarrats, N., Kiourtis, C., Müller, M., Green, A. R., Adams, P. D., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.104 · Cited by 149
“We confirmed a senescence phenotype for both populations by upregulation of key senescence genes (Figure 1D) cyclin-dependent kinase 1a (CDKN1A) and cyclin-dependent kinase inhibitor 2b (CDKN2B) and SASP factors interleukin 8 (IL8), interleukin 6 (IL6), and interleukin 1B (IL1B) (p < 0.05 for all genes; Figure 1D).”
BackgroundInfluentialLeontieva, O. V., & Blagosklonny, M. V. (2010) · Aging · doi:10.18632/aging.100265 · Cited by 160
“nent loss of proliferative potential [6-8].”
Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program
Blagosklonny, M. V. (2010) · Cell Cycle · doi:10.4161/cc.9.16.13120 · Cited by 160
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
Madden, E. C., Gorman, A. M., Logue, S. E., & Samali, A. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.020 · Cited by 159
Vascular smooth muscle cell senescence and age-related diseases: State of the art
Chi, C., Li, D.-J., Jiang, Y.-J., Tong, J., Fu, H., Wu, Y.-H., & Shen, F.-M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.015 · Cited by 158
Faces of cellular senescence in skin aging
Ho, C. Y., & Dreesen, O. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111525 · Cited by 158
“Specifically, the depletion of mitochondrial sirtuins led to the mitochondrial-dysfunction-associated senescence (miDAS) phenotype characterised by lower NAD+/NADH ratios and a distinct SASP that was independent of the IL-1 pathway.”
BackgroundInfluentialZhang, B., Fu, D., Xu, Q., Cong, X., Wu, C., Zhong, X., Ma, Y., Lv, Z., Chen, F., Han, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04010-4 · Cited by 157
Yang, L., & Lin, P. C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.001 · Cited by 155
“Ras activation exacerbated pro-malignant paracrine activities through IL-6 and IL-8 [69].”
BackgroundDeeks, S. G., Verdin, E. M., & McCune, J. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.05.004 · Cited by 181
“Senescent cells accumulate in various organs and tissues during aging, and have been proposed to play a direct causative role in the aging process via secretion of proinflammatory cytokines [13,14,15 ,16].”
BackgroundYu, Y., Schleich, K., Yue, B., Ji, S., Lohneis, P., Kemper, K., Silvis, M. R., Qutob, N., van Rooijen, E., Werner-Klein, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.002 · Cited by 156
“…secretory phenotype (SASP) and the NF-κB signaling pathway as a major driver of pro-inflammatory SASP factors (increased expression) (Coppe et al., 2008; Kuilman et al., 2008), indicating that knock-down of LSD1 or JMJD2C indeed re-established a full-featured senescence condition…”
BackgroundRossiello, F., Herbig, U., Longhese, M. P., Fumagalli, M., & di Fagagna, F. D. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2014.06.009 · Cited by 180
The Senescence Markers p16INK4A, p14ARF/p19ARF, and p21 in Organ Development and Homeostasis
Wagner, K.-D., & Wagner, N. (2022) · Cells · doi:10.3390/cells11121966 · Cited by 156
Mosieniak, G., Adamowicz, M., Alster, O., Jaskowiak, H., Szczepankiewicz, A. A., Wilczynski, G. M., Ciechomska, I. A., & Sikora, E. (2012) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2012.05.004 · Cited by 168
“Although we did not examine SASP in the curcumin-treated HCT116 cells, it was shown by others that the secretory phenotype is also observed in prostate cancer cells induced to senescence by X radiation (Coppe et al., 2008).”
Cellular Senescence and the Biology of Aging, Disease, and Frailty
LeBrasseur, N. K., Tchkonia, T., & Kirkland, J. L. (2015) · Nestlé Nutrition Institute Workshop Series · doi:10.1159/000382054 · Cited by 147
Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8
Walle, T., Kraske, J. A., Liao, B., Lenoir, B., Timke, C., Halbach, E. V. B. U., Tran, F., Griebel, P., Albrecht, D., Ahmed, A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abh4050 · Cited by 168
Prostatic fibrosis, lower urinary tract symptoms, and BPH
Rodriguez-Nieves, J. A., & Macoska, J. A. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.149 · Cited by 168
The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype
Hari, P., Millar, F. R., Tarrats, N., Birch, J., Quintanilla, A., Rink, C. J., Fernández-Duran, I., Muir, M., Finch, A. J., Brunton, V. G., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw0254 · Cited by 154
Oxidative stress, cellular senescence and ageing
Pole, A., Department of Biochemistry and Molecular Medicine, S. O. M. A. H. S., Dimri, M., & P. Dimri, G. (2016) · AIMS Molecular Science · doi:10.3934/molsci.2016.3.300 · Cited by 155
“The SASP factors mediate pro-oncogenic effects of senescence via cell non-autonomous mechanisms which involve a paracrine signaling [83,96,165].”
BackgroundInfluentialNiu, J., Shi, Y., Tan, G., Yang, C. H., Fan, M., Pfeffer, L. M., & Wu, Z. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355495 · Cited by 166
“By paracrine effects of SASP, senescent cells may promote the proliferation and tumorigenesis of epithelial cells, stimulate angiogenesis, trigger an epithelial to mesenchymal transition, accelerate the invasion of malignant cells, and facilitate the growth of secondary tumors in cancer patients treated with DNA-damag…”
BackgroundRetractedCOVID-19 and cellular senescence
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153
Kang, D., Shin, J., Cho, Y., Kim, H.-S., Gu, Y.-R., Kim, H., You, K. T., Chang, M. J., Chang, C. B., Kang, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aar6659 · Cited by 156
Servais, C., & Erez, N. (2013) · The Journal of Pathology · doi:10.1002/path.4103 · Cited by 152
Brain energy metabolism: Astrocytes in neurodegenerative diseases.
Chen, Z., Yuan, Z., Yang, S., Zhu, Y., Xue, M., Zhang, J., & Leng, L. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13982 · Cited by 153
The effect of environmental chemicals on the tumor microenvironment
Casey, S. C., Vaccari, M., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Barcellos-Hoff, M. H., Brown, D. G., Chapellier, M., Christopher, J., Curran, C. S., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv035 · Cited by 152
“microenvironment through the production of cytokines and growth factors and recruitment of immune cells (13).”
BackgroundFibrin and Fibrinolysis in Cancer
Kwaan, H. C., & Lindholm, P. F. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1688495 · Cited by 162
Role of Epicardial Adipose Tissue in Health and Disease: A Matter of Fat?
Gaborit, B., Sengenes, C., Ancel, P., Jacquier, A., & Dutour, A. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c160034 · Cited by 151
“shown to induce or sustain the age-related inflammation state (52, 191, 241, 352).”
The role of exosomes and microRNAs in senescence and aging
Xu, D., & Tahara, H. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.010 · Cited by 162
Activation of immunosuppressive network in the aging process
Salminen, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100998 · Cited by 151
Extracellular matrix alterations in senescent cells and their significance in tissue homeostasis
Mavrogonatou, E., Pratsinis, H., Papadopoulou, A., Karamanos, N. K., & Kletsas, D. (2019) · Matrix Biology · doi:10.1016/j.matbio.2017.10.004 · Cited by 153
Sultana, Z., Maiti, K., Dedman, L., & Smith, R. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.11.567 · Cited by 162
The role of cellular senescence and SASP in tumour microenvironment
Takasugi, M., Yoshida, Y., Hara, E., & Ohtani, N. (2023) · The FEBS Journal · doi:10.1111/febs.16381 · Cited by 144
Khan, S. Y., Awad, E. M., Oszwald, A., Mayr, M., Yin, X., Waltenberger, B., Stuppner, H., Lipovac, M., Uhrin, P., & Breuss, J. M. (2017) · Scientific Reports · doi:10.1038/srep39501 · Cited by 148
Whole Chromosome Instability induces senescence and promotes SASP
Andriani, G. A., Almeida, V. P., Faggioli, F., Mauro, M., Tsai, W. L., Santambrogio, L., Maslov, A., Gadina, M., Campisi, J., Vijg, J., et al. (2016) · Scientific Reports · doi:10.1038/srep35218 · Cited by 146
Self-citationRapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice
Komarova, E. A., Antoch, M. P., Novototskaya, L. R., Chernova, O. B., Paszkiewicz, G., Leontieva, O. V., Blagosklonny, M. V., & Gudkov, A. V. (2012) · Aging · doi:10.18632/aging.100498 · Cited by 146
Long non-coding RNA H19 regulates endothelial cell aging via inhibition of STAT3 signalling
Hofmann, P., Sommer, J., Theodorou, K., Kirchhof, L., Fischer, A., Li, Y., Perisic, L., Hedin, U., Maegdefessel, L., Dimmeler, S., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvy206 · Cited by 147
Single-cell senescence identification reveals senescence heterogeneity, trajectory, and modulators
Tao, W., Yu, Z., & Han, J.-D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.009 · Cited by 147
Senescent cells communicate via intercellular protein transfer
Biran, A., Perelmutter, M., Gal, H., Burton, D. G. A., Ovadya, Y., Vadai, E., Geiger, T., & Krizhanovsky, V. (2015) · Genes & Development · doi:10.1101/gad.259341.115 · Cited by 139
“Senescent cells can impact their microenvironment and influence tissue homeostasis with both positive and negative outcomes, depending on physiological context (Acosta et al. 2008; Coppe et al. 2008; Kuilman et al. 2008; Wajapeyee et al. 2008; Calabrese et al. 2009).”
Cellular Senescence as the Causal Nexus of Aging
Bhatia-Dey, N., Kanherkar, R. R., Stair, S. E., Makarev, E. O., & Csoka, A. B. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00013 · Cited by 146
“Age-associated accumulation of senescent cells in various tissues and organs causes functional disruption of tissue structure, partly through appearance and accumulation of senescent-associated secretory proteins (Coppé et al., 2008; Rodier and Campisi, 2011).”
BackgroundPlacental membrane aging and HMGB1 signaling associated with human parturition
Menon, R., Behnia, F., Polettini, J., Saade, G. R., Campisi, J., & Velarde, M. (2016) · Aging · doi:10.18632/aging.100891 · Cited by 143
Self-citationTumors induce complex DNA damage in distant proliferative tissues in vivo
Redon, C. E., Dickey, J. S., Nakamura, A. J., Kareva, I. G., Naf, D., Nowsheen, S., Kryston, T. B., Bonner, W. M., Georgakilas, A. G., & Sedelnikova, O. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008260107 · Cited by 144
Cellular senescence in musculoskeletal homeostasis, diseases, and regeneration
Wan, M., Gray-Gaillard, E. F., & Elisseeff, J. H. (2021) · Bone Research · doi:10.1038/s41413-021-00164-y · Cited by 163
“Not only do SnCs with SASP induce autocrine reinforcement, but they also communicate with neighboring cells in a paracrine manner to propagate the stress response in the tissue microenvironment.(56,61,62) Of note, the paracrine effects of the SASP can be beneficial or detrimental depending on the tissue context.”
BackgroundThe multifaceted role of the SASP in atherosclerosis: from mechanisms to therapeutic opportunities
Sun, Y., Wang, X., Liu, T., Zhu, X., & Pan, X. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00815-5 · Cited by 168
Self-citationBiomarkers to identify and isolate senescent cells
Matjusaitis, M., Chin, G., Sarnoski, E. A., & Stolzing, A. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.05.003 · Cited by 144
“One study has defined many of the factors which are secreted by aged human fibroblasts and epithelial cells (Campisi et al., 2008).”
Dissecting Aging and Senescence—Current Concepts and Open Lessons
Schmeer, C., Kretz, A., Wengerodt, D., Stojiljkovic, M., & Witte, O. W. (2019) · Cells · doi:10.3390/cells8111446 · Cited by 144
“Induction of the SASP involves activation of several signaling pathways such as DDR, p38 MAPK, and mechanistic target of rapamycin (mTOR) [73,79].”
BackgroundHassona, Y., Cirillo, N., Heesom, K., Parkinson, E. K., & Prime, S. S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.438 · Cited by 144
Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development
Luo, X., Fu, Y., Loza, A. J., Murali, B., Leahy, K. M., Ruhland, M. K., Gang, M., Su, X., Zamani, A., Shi, Y., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.016 · Cited by 141
“To determine if the activation of senescence occurred in GFP+ osteoblasts, we co-stained bone sections from FASST mice for GFP and interleukin-6 (IL-6), a well-characterized SASP factor readily expressed in senescent human and mouse fibroblasts (Coppé et al., 2008, 2010).”
InfluentialGuidelines for the selection of functional assays to evaluate the hallmarks of cancer
Menyhárt, O., Harami-Papp, H., Sukumar, S., Schäfer, R., Magnani, L., de Barrios, O., & Győrffy, B. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.10.002 · Cited by 141
“Cancer cell immortality can be assessed by analyzing expression of key enzymes and regulators as listed in Table 6 [101, 102, 105-107].”
BackgroundPateras, I. S., Havaki, S., Nikitopoulou, X., Vougas, K. N., Townsend, P. A., Panayiotidis, M. I., Georgakilas, A. G., & Gorgoulis, V. G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.011 · Cited by 156
“…must be removed as well, because they can systemically affect neighboring cells by triggering various pathologies, including cancer, due to their so-called senescenceassociated secretory phenotype (SASP), despite being a beneficial response, particularly in oncogenic events (Coppé et al., 2008).”
BackgroundCellular Senescence Promotes Skin Carcinogenesis through p38MAPK and p44/42MAPK Signaling
Alimirah, F., Pulido, T., Valdovinos, A., Alptekin, S., Chang, E., Jones, E., Diaz, D. A., Flores, J., Velarde, M. C., Demaria, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0108 · Cited by 128
“11), is now recognized as a significant driver of many age-related pathologies (11, 12).”
BackgroundInfluentialSelf-citationExperimental Models of Sarcopenia: Bridging Molecular Mechanism and Therapeutic Strategy
Mankhong, S., Kim, S., Moon, S., Kwak, H., Park, D., & Kang, J. (2020) · Cells · doi:10.3390/cells9061385 · Cited by 162
“Importantly, the SASP can have either beneficial or detrimental effects depending on the specific composition of distinct cell types and different senescence-inducing stressors [20].”
BackgroundXu, Q., Long, Q., Zhu, D., Fu, D., Zhang, B., Han, L., Qian, M., Guo, J., Xu, J., Cao, L., et al. (2019) · Aging Cell · doi:10.1111/acel.13027 · Cited by 139
“…or chemok‐ ines per se, such as IL‐8 and CXCL3, diverse growth factors including amphiregulin (AREG) are produced by senescent human stromal cells (Coppe et al., 2008; Sun et al., 2012), suggesting that the impact of the SASP on tumor progression could be complicated and multidi‐ mensional.”
BackgroundSelf-citationTacutu, R., Budovsky, A., Yanai, H., & Fraifeld, V. E. (2011) · Aging · doi:10.18632/aging.100413 · Cited by 143
“Such an activation eventually leads to an enhanced secretion of cytokines, chemokines, proteases and ROS by senescent cells [49], collectively termed as the senescenceassociated secretory phenotype (SASP) [9, 50].”
BackgroundAdult-onset, short-term dietary restriction reduces cell senescence in mice
Wang, C., Maddick, M., Miwa, S., Jurk, D., Czapiewski, R., Saretzki, G., Langie, S. A. S., Godschalk, R. W. L., Cameron, K., & von Zglinicki, T. (2010) · Aging · doi:10.18632/aging.100196 · Cited by 142
“Senescent cells are not simply incompetent of proliferating; they display major alterations to their gene expression profiles [35] and secrete bioactive molecules including matrix-degrading enzymes [36], inflammatory cytokines [21,22,37] and ROS [23].”
BackgroundMicrobiota, NASH, HCC and the potential role of probiotics
Brandi, G., De Lorenzo, S., Candela, M., Pantaleo, M. A., Bellentani, S., Tovoli, F., Saccoccio, G., & Biasco, G. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx007 · Cited by 142
DNA damage and innate immunity: links and trade-offs
Chatzinikolaou, G., Karakasilioti, I., & Garinis, G. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.06.003 · Cited by 158
DNA Damage Triggers a Chronic Autoinflammatory Response, Leading to Fat Depletion in NER Progeria
Karakasilioti, I., Kamileri, I., Chatzinikolaou, G., Kosteas, T., Vergadi, E., Robinson, A. R., Tsamardinos, I., Rozgaja, T. A., Siakouli, S., Tsatsanis, C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.011 · Cited by 140
“Previous studies suggest that human cells induced to senesce by genotoxic stress secrete several proinflammatory factors (Coppé et al., 2008).”
BackgroundSILAC Analysis Reveals Increased Secretion of Hemostasis-Related Factors by Senescent Cells
Wiley, C. D., Liu, S., Limbad, C., Zawadzka, A. M., Beck, J., Demaria, M., Artwood, R., Alimirah, F., Lopez-Dominguez, J.-A., Kuehnemann, C., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.049 · Cited by 137
“In agreement with previous work (Coppé et al., 2008), the patterns were not identical.”
BackgroundResultInfluentialFoxM1 repression during human aging leads to mitotic decline and aneuploidy-driven full senescence
Macedo, J. C., Vaz, S., Bakker, B., Ribeiro, R., Bakker, P. L., Escandell, J. M., Ferreira, M. G., Medema, R., Foijer, F., & Logarinho, E. (2018) · Nature Communications · doi:10.1038/s41467-018-05258-6 · Cited by 131
Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes
Eckhardt, B. A., Rowsey, J. L., Thicke, B. S., Fraser, D. G., O’Grady, K. L., Bondar, O. P., Hines, J. M., Singh, R. J., Thoreson, A. R., Rakshit, K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135236 · Cited by 130
“Finally, we used rt-qPCR to measure the mRNA expression of a panel of 36 established SASP genes (29) in the osteocyte-enriched bone samples of T2D versus Control mice (Figure 8A-B).”
MethodFrescas, D., Roux, C. M., Aygun-Sunar, S., Gleiberman, A. S., Krasnov, P., Kurnasov, O. V., Strom, E., Virtuoso, L. P., Wrobel, M., Osterman, A. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614661114 · Cited by 140
“Moreover, the presence of SASP factors has also been shown to induce an epithelial–mesenchyme transition and angiogenesis that supports cancer cell invasiveness (5).”
BackgroundAmeziane-El-Hassani, R., Talbot, M., de Souza Dos Santos, M. C., Al Ghuzlan, A., Hartl, D., Bidart, J.-M., De Deken, X., Miot, F., Diallo, I., de Vathaire, F., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420707112 · Cited by 140
“Persistent changes precede the establishment of senescenceassociated phenotypes, including growth arrest (26–28) and senescence-associated secretory phenotype (SASP), with potent autocrine and paracrine activities (18, 29).”
BackgroundNess, K. K., Kirkland, J. L., Gramatges, M. M., Wang, Z., Kundu, M., McCastlain, K., Li-Harms, X., Zhang, J., Tchkonia, T., Pluijm, S. M. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7467 · Cited by 140
Role of the inflammation-autophagy-senescence integrative network in osteoarthritis
Vinatier, C., Domínguez, E., Guicheux, J., & Caramés, B. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00706 · Cited by 135
Circadian clock protein BMAL1 regulates cellular senescence in vivo
Khapre, R. V., Kondratova, A. A., Susova, O., & Kondratov, R. V. (2011) · Cell Cycle · doi:10.4161/cc.10.23.18381 · Cited by 138
Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone Loss
Chandra, A., Lagnado, A. B., Farr, J. N., Monroe, D. G., Park, S., Hachfeld, C., Tchkonia, T., Kirkland, J. L., Khosla, S., Passos, J. F., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3978 · Cited by 138
Sedic, M., Skibinski, A., Brown, N., Gallardo, M., Mulligan, P., Martinez, P., Keller, P. J., Glover, E., Richardson, A. L., Cowan, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8505 · Cited by 137
Lozano-Torres, B., Estepa-Fernández, A., Rovira, M., Orzáez, M., Serrano, M., Martínez-Máñez, R., & Sancenón, F. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0108-0 · Cited by 140
Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy
Morein, D., Erlichman, N., & Ben‐Baruch, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00952 · Cited by 146
“In this respect, it was found also that fibroblast-derived SASP induced EMT in nonaggressive breast tumor cells, with direct roles of CXCL8 + IL-6 in promoting tumor cell invasiveness (67).”
BackgroundThe Chromatin Landscape of Cellular Senescence
Criscione, S. W., Teo, Y. V., & Neretti, N. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.09.005 · Cited by 137
Li, M., You, L., Xue, J., & Lu, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00522 · Cited by 137
“Initiation and maintenance of SASP producing requires ATM and the downstream NF-κB-dependent transcriptional program as the master regulators but not the cell cycle arrest enforcers p53 and Rb (Coppe et al., 2008; Rodier et al., 2009; Ferrand et al., 2015).”
BackgroundTRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells
Biroccio, A., Cherfils‐Vicini, J., Augereau, A., Pinte, S., Bauwens, S., Ye, J., Simonet, T., Horard, B., Jamet, K., Cervera, L., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2774 · Cited by 149
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 161
Stout, M. B., Tchkonia, T., Pirtskhalava, T., Palmer, A. K., List, E. O., Berryman, D. E., Lubbers, E. R., Escande, C., Spong, A., Masternak, M. M., et al. (2014) · Aging · doi:10.18632/aging.100681 · Cited by 136
“Senescent cells typically have a pro-inflammatory secretory profile, termed the senescence-associated secretory phenotype (SASP) [29-32], which can adversely affect the local microenvironment through tissue remodeling and apoptosis [32].”
BackgroundThe role of cellular senescence in skin aging and age-related skin pathologies
Chin, T., Lee, X. E., Ng, P. Y., Lee, Y., & Dreesen, O. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1297637 · Cited by 138
Shimabukuro, M. K., Langhi, L. G. P., Cordeiro, I., Brito, J. M., Batista, C. M. D. C., Mattson, M. P., & de Mello Coelho, V. (2016) · Scientific Reports · doi:10.1038/srep23795 · Cited by 136
NADPH Oxidases and Mitochondria in Vascular Senescence
Salazar, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051327 · Cited by 133
“NF-κB is the major regulator of a large set of SASP components, including IL1α, IL6, and IL8 [7,10].”
BackgroundInfluentialCancer and Aging - the Inflammatory Connection
Zinger, A., Cho, W. C., & Ben-Yehuda, A. (2017) · Aging and disease · doi:10.14336/ad.2016.1230 · Cited by 136
Elevated Local Senescence in Diabetic Wound Healing Is Linked to Pathological Repair via CXCR2
Wilkinson, H. N., Clowes, C., Banyard, K. L., Matteuci, P., Mace, K. A., & Hardman, M. J. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.01.005 · Cited by 135
DNA single-strand break-induced DNA damage response causes heart failure
Higo, T., Naito, A. T., Sumida, T. S., Shibamoto, M., Okada, K., Nomura, S., Nakagawa, A., Yamaguchi, T., Sakai, T., Hashimoto, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15104 · Cited by 147
Identifying specific functional roles for senescence across cell types
(2024) · doi:10.1016/j.cell.2024.09.021 · Cited by 139
Immunosenescence: signaling pathways, diseases and therapeutic targets
Fu, Y., Wang, B., Alu, A., Hong, W., Hong, L., He, X., Shi, H., Cheng, P., & Yang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02371-z · Cited by 187
Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma
Salam, R., Saliou, A., Bielle, F., Bertrand, M., Antoniewski, C., Carpentier, C., Alentorn, A., Capelle, L., Sanson, M., Huillard, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36124-9 · Cited by 132
Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications
Yang, Q., Xu, J. B., Gu, J., Shi, H., Zhang, J., Zhang, J., Chen, Z., Fang, X., Zhu, T., & Zhang, X. (2022) · Advanced Science · doi:10.1002/advs.202201609 · Cited by 162
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.